These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 17502864)

  • 21. [Infectious complications associated with the use of tumor necrosis factor antagonist drugs: a review].
    García-Lechuz Moya JM
    Enferm Infecc Microbiol Clin; 2005 Nov; 23(9):551-9. PubMed ID: 16324568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
    Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
    Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs.
    Kohno T; Tam LT; Stevens SR; Louie JS
    J Investig Dermatol Symp Proc; 2007 May; 12(1):5-8. PubMed ID: 17502862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How tumour necrosis factor blockers interfere with tuberculosis immunity.
    Harris J; Keane J
    Clin Exp Immunol; 2010 Jul; 161(1):1-9. PubMed ID: 20491796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
    Finckh A; Simard JF; Gabay C; Guerne PA;
    Ann Rheum Dis; 2006 Jun; 65(6):746-52. PubMed ID: 16339288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.
    Van den Brande JM; Braat H; van den Brink GR; Versteeg HH; Bauer CA; Hoedemaeker I; van Montfrans C; Hommes DW; Peppelenbosch MP; van Deventer SJ
    Gastroenterology; 2003 Jun; 124(7):1774-85. PubMed ID: 12806611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Autoimmune aspects of treatment with TNF-alpha inhibitors].
    Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M
    Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
    Bonafede MM; Gandra SR; Fox KM; Wilson KL
    J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study.
    Lim LL; Fraunfelder FW; Rosenbaum JT
    Arthritis Rheum; 2007 Oct; 56(10):3248-52. PubMed ID: 17907169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
    van Dartel SA; Fransen J; Kievit W; Flendrie M; den Broeder AA; Visser H; Hartkamp A; van de Laar MA; van Riel PL
    Ann Rheum Dis; 2013 Jun; 72(6):895-900. PubMed ID: 22887849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytokine production from stimulated whole blood cultures in rheumatoid arthritis patients treated with various TNF blocking agents.
    Popa C; Barrera P; Joosten LA; van Riel PL; Kullberg BJ; van der Meer JW; Netea MG
    Eur Cytokine Netw; 2009 Jun; 20(2):88-93. PubMed ID: 19541595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fungal infections complicating tumor necrosis factor alpha blockade therapy.
    Tsiodras S; Samonis G; Boumpas DT; Kontoyiannis DP
    Mayo Clin Proc; 2008 Feb; 83(2):181-94. PubMed ID: 18241628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
    J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study.
    Schabert VF; Bruce B; Ferrufino CF; Globe DR; Harrison DJ; Lingala B; Fries JF
    Curr Med Res Opin; 2012 Apr; 28(4):569-80. PubMed ID: 22236091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [What is the risk of malignancies associated with anti-TNF therapy?].
    Jonville-Béra AP; Lorette G
    Presse Med; 2009 Sep; 38(9):1209-10. PubMed ID: 19324517
    [No Abstract]   [Full Text] [Related]  

  • 38. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis.
    Koike R; Takeuchi T; Eguchi K; Miyasaka N;
    Mod Rheumatol; 2007; 17(6):451-8. PubMed ID: 18084695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
    Gniadecki R; Kragballe K; Dam TN; Skov L
    Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data.
    Askling J; Fahrbach K; Nordstrom B; Ross S; Schmid CH; Symmons D
    Pharmacoepidemiol Drug Saf; 2011 Feb; 20(2):119-30. PubMed ID: 21254282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.